Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Outlook Therapeutics Inc (OTLKW)

Outlook Therapeutics Inc (OTLKW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ -58,983 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.01 +200.00%
on 02/16/22
0.10 -68.75%
on 02/11/22
-0.02 (-40.00%)
since 01/14/22
3-Month
0.01 +200.00%
on 02/16/22
0.30 -90.00%
on 12/03/21
-0.13 (-81.18%)
since 11/16/21
52-Week
0.01 +200.00%
on 02/16/22
1.44 -97.91%
on 02/17/21
-1.32 (-97.79%)
since 02/16/21

Most Recent Stories

More News
Outlook Therapeutics® Streamlines Operations

OTLK : 1.4400 (+3.60%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

OTLK : 1.4400 (+3.60%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics® Announces Executive Leadership Transition

OTLK : 1.4400 (+3.60%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial

OTLK : 1.4400 (+3.60%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference

OTLK : 1.4400 (+3.60%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment

OTLK : 1.4400 (+3.60%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2022 and Reiterates Key Anticipated Near-Term Milestones

Planned re-submission of ONS-5010 / LYTENAVAâ„¢ (bevacizumab-vikg) Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) on track ...

OTLKW : 0.03 (-1.96%)
OTLK : 1.4400 (+3.60%)
Outlook to Present at the H.C. Wainwright 2nd Annual Ophthalmology Conference

ISELIN, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop...

OTLKW : 0.03 (-1.96%)
OTLK : 1.4400 (+3.60%)
Outlook Therapeutics Announces Full Cash Pre-Payment of Convertible Promissory Note

ISELIN, N.J., July 05, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop...

OTLKW : 0.03 (-1.96%)
OTLK : 1.4400 (+3.60%)
Outlook Therapeutics Confirms Status of Biologics License Application (BLA) Submission for ONS-5010

Outlook Therapeutics reiterates expected re-submission of BLA by September 2022 following receipt of additional correspondence from U.S. Food and Drug...

OTLKW : 0.03 (-1.96%)
OTLK : 1.4400 (+3.60%)

Key Turning Points

3rd Resistance Point 0.07
2nd Resistance Point 0.05
1st Resistance Point 0.04
Last Price 0.03
1st Support Level 0.02
2nd Support Level N/A
3rd Support Level N/A

See More

52-Week High 1.44
Fibonacci 61.8% 0.89
Fibonacci 50% 0.72
Fibonacci 38.2% 0.55
Last Price 0.03
52-Week Low 0.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar